Skip to main content
Back
NRIX logo

Nurix Therapeutics, Inc.

Data quality: 100%
NRIX
NASDAQ Healthcare Biotechnology
$14.69
▲ $0.26 (1.80%)
Mkt Cap: 1.27B
Day Range
$14.59 $15.48
52-Week Range
$8.18 $22.50
Volume
838,461
50D / 200D Avg
$16.70 / $13.53
Prev Close
$14.43

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -4.8 0.4
P/B 2.4 2.9
ROE % -49.6 3.7
Net Margin % -314.9 3.8
Rev Growth 5Y % 29.6 10.0
D/E 0.1 0.2

Key Takeaways

Revenue grew 29.62% annually over 5 years — strong growth
Debt/Equity of 0.10 — conservative balance sheet
Negative free cash flow of -263.47M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 24.33%

Growth

Revenue Growth (5Y)
29.62%
Revenue (1Y)53.95%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-49.63%
ROIC-36.04%
Net Margin-314.90%
Op. Margin-340.16%

Safety

Debt / Equity
0.10
Current Ratio7.02
Interest Coverage0.00

Valuation

P/E Ratio
-4.81
P/B Ratio2.36
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 53.95% Revenue Growth (3Y) 4.44%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 29.62% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 83.98M Net Income (TTM) -264.46M
ROE -49.63% ROA -38.43%
Gross Margin 77.55% Operating Margin -340.16%
Net Margin -314.90% Free Cash Flow (TTM) -263.47M
ROIC -36.04% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.10 Current Ratio 7.02
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -4.81 P/B Ratio 2.36
P/S Ratio 15.16 PEG Ratio -0.94
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.27B Enterprise Value 1.08B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 83.98M 54.55M 76.99M 38.63M 29.75M
Net Income -264.46M -193.57M -143.95M -180.36M -117.19M
EPS (Diluted) -3.05 -2.88 -2.65 -3.71 -2.73
Gross Profit 65.12M -167.08M -112.16M -145.87M -86.68M
Operating Income -285.67M -213.03M -155.06M -183.87M -117.89M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 688.14M 669.34M 355.60M 416.76M 476.77M
Total Liabilities 149.39M 142.35M 155.11M 113.06M 134.47M
Shareholders' Equity 538.75M 526.99M 200.49M 303.70M 342.30M
Total Debt 55.73M 28.30M 30.61M 11.96M 13.04M
Cash & Equivalents 246.96M 110.00M 54.63M 64.47M 80.51M
Current Assets 606.82M 619.39M 295.50M 318.45M 311.12M
Current Liabilities 86.47M 95.85M 86.96M 70.66M 66.26M